효소면역측정법(ELISA) : 세계 시장 인사이트, 경쟁 환경 및 시장 예측(-2030년)

ELISA MARKET BY PRODUCT TYPE (KITS AND REAGENTS, ELISA SYSTEMS, AND OTHERS), BY APPLICATION (HIV, PREGNANCY TESTING, COVID-19, AND OTHERS), BY END-USER (HOSPITALS AND DIAGNOSTIC LABS, PHARMACEUTICAL AND BIOTECH INDUSTRIES, AND OTHERS), BY GEOGRAPHY IS ESTIMATED TO REGISTER GROWTH AT A REMARKABLE CAGR FORECAST DURING 2024-2030 OWING TO SURGE IN PREVALENCE OF INFECTIOUS DISEASES AND CONTINUOUS RESEARCH AND DEVELOPMENT ACTIVITIES HAPPENING IN PHARMACEUTICAL AND BIOTECH INDUSTRIES.

The global ELISA market was valued at USD 5.34 billion in 2023, growing at a CAGR of 6.07% during the forecast period from 2024 to 2030 to reach USD 7.58 billion by 2030. The ELISA market is slated to witness prosperity owing to factors such as growing prevalence of infectious diseases such as HIV, tuberculosis, malaria, and hepatitis B among others, growing application of ELISA for drug abuse testing, and the growing focus on improving the accuracy, portability, affordability, and usability of ELISA for end users are further expected to result in the appreciable revenue growth in the ELISA Market during the forecast period (2024-2030).

ELISA MARKET DYNAMICS:

One of the noteworthy drivers of the ELISA market is the elevation in cases of sexually transmitted diseases worldwide. For instance, according to World Health Organization (WHO) 2022, worldwide around 1 million people acquire STDs every day. Also, as per the same source, it was estimated that there were around 129 million cases of chlamydia, 7.1 million cases of syphilis, 82 million cases of gonorrhea, and around 156 million cases of trichomoniasis recorded in 2020.

The different cancer types affecting millions of people worldwide is another driver for ELISA market. For instance as per the World Health Organization (WHO) 2022, there were around 2.26 million cases of breast cancer, 2.21 million cases of lung cancer 1.93 million cases of colon and rectal cancer, recorded in 2020. Also, the rising awareness on cancer such as lung, breast, and prostate cancer amongst the adult population as well as recommendation of annual tests of biomarkers of these diseases by doctors is going to accelerate the market of ELISA.

The rising application of ELISA in drug abuse testing is likely to increase its demand, thus positively impacting the market growth for ELISA market. For instance, according United Nations Office on Drugs and Crime (UNODC) 2022, around 275 million people used drugs worldwide in the last year, while over 36 million people suffered from drug use disorders. The number of drugs including Tetrahydrocannabinol (THC), methadone, opioids, benzodiazepines, and others are abused by many and ELISA is capable of detecting the presence of these drugs in various biological specimens such as hair, blood, urine, oral fluid, serum, plasma, and others.

Also, the continuous research and development across pharmaceutical and biotechnology industries is again leading towards the growth in ELISA market.

However, the availability of alternative products and limitations associated with ELISA may act as restraining factors to the ELISA market growth.

During the period of COVID-19 infection, the ELISA market witnessed slight growth owing to increased number of cases of leading to increased need of diagnostic tools and technologies. The COVID-19 pandemic resulted in vast FDA approvals of ELISA based diagnostic kits under emergency use status which further led to the development of sensitive and reliable ELISA based diagnostic kits for the detection of Sars COV-2. Thus, positively impacting the ELISA market. The pandemic scenario has been uplifting for the ELISA market during the forecast period from 2024-2030.

ELISA MARKET SEGMENT ANALYSIS:

ELISA Market by Product Type (Kits and Reagents, Elisa Systems, and Others), Application (HIV, Pregnancy Testing, COVID- 19, and Others), End-User (Hospitals, Biotechnology Industries, Pharmaceutical Industries and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Based on the product type segment of the ELISA market, the kits and reagents segment is going to register a significant market growth.

ELISA kits and reagents are widely utilized for the rapid detection and quantification of antibodies against bacteria, viruses, as well as other material antigens. The hundreds of different proteins and molecules including cytokines, growth factors, markers for infectious diseases, diabetes and tumor, drugs and small molecules can be detected through ELISA kits and reagents.

These are effective, quick, convenient, and accurate research tool for the detection and quantitation of targets of interest in cultures and samples.

Therefore, considering the growing demand for this product type, numerous new products are being launched in the market. In September 2022, J Mitra announced the launch of their 4th Generation Elisa-based HCV Test-the HCV Gen 4 Ag & Ab Microlisa. The kit is particularly intended for screening blood donations to identify and eliminate the infected units of blood and for clinical diagnostic testing of Hepatitis C.

Therefore, considering the advantages and applications associated with ELISA kits and reagents and their growing popularity among end users, this product category is expected to generate considerable revenue thereby pushing the overall growth of the global ELISA market during the forecast period.

NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL ELISA MARKET:

Among all the regions, North America is expected to lead in revenue generation in the global ELISA market. This can be ascribed to the presence of large patient pool associated with infectious diseases, government support, high consumer awareness regarding new market launches and a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region.

The increasing prevalence of infectious diseases such as malaria, tuberculosis, hepatitis B, and other are likely to accelerate the growth of ELISA market. As per Centers for Diseases Control and Prevention 2022, around 7,860 new cases of tuberculosis were reported in the US in 2022. According to CDC 2022, each year nearly 2,000 cases of malaria are reported in the US.

Moreover, increasing number of blood donations and blood transfusions in the region necessitates the use of ELISA kits for the detection of hepatitis B and other infections in order to avoid the risk of transfusion of infected blood in patients. For instance, as per the Centers for Disease Control and Prevention 2020, there are around 13.2 million blood donors in the United States, resulting in a total of 17.2 million transfused blood product units per year.

One of the prominent factors supporting the growth of the North America ELISA market is the extensive use of ELISA in the detection of tumor markers indicating cancer development. As per American Cancer Society 2022, it has been estimated that around 1.9 million new cancer cases will be diagnosed in the US in 2022. Also, according to Centers for Disease Control and Prevention (CDC) 2022, around 1,752,735 new cancer cases were reported in 2019 in the US.

Therefore, the presence of large number of patients coupled with the increasing focus of manufacturers on launching new products in the market is expected to bolster the growth of the ELISA market in the United States during the forecast period.

ELISA MARKET KEY PLAYERS:

Some of the key market players operating in the ELISA market includes Abbott, F. Hoffmann-La Roche Ltd, Erba Mannheim, Synbiotik, Maccura Biotechnology Co., Ltd., Thermo Fisher Scientific, DiaSorin, PerkinElmer Inc., Diatron, Werfen, ALPCO, Agilent, InBios International Inc., Awareness Technology Inc., Elabscience Biotechnology Inc., J. Mitra & Co. Pvt. Ltd., Rayto Life and Analytical Sciences Co.,Ltd., BD, Trivitron Healthcare, and others.

RECENT DEVELOPMENTAL ACTIVITIES IN ELISA MARKET:

In February 2022, Agilent Technologies Inc. announced the launch of the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit for the qualitative detection of immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human serum or plasma

In April 2020, ERBA Mannheim announced the launch of its CE ErbaLisa® COVID-19 ELISA kits

In November 2020, Enzo announced the launch of portable microplate reader for its elisa and other assay kits

KEY TAKEAWAYS FROM THE ELISA MARKET REPORT STUDY

• Market size analysis for current ELISA Market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the ELISA market.
• Top key product/services/technology developments, mergers, acquisitions, partnerships, joint ventures happened for last 3 years
• Key companies dominating the global ELISA market.
• Various opportunities available for the other competitor in the ELISA market space.
• What are the top performing segments in 2023? How these segments will perform in 2030.
• Which is the top-performing regions and countries in the current ELISA market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for ELISA market growth in the coming future?

TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS ELISA MARKET REPORT STUDY

• ELISA products providers
• Research organizations and consulting companies
• ELISA -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in ELISA
• Various end users who want to know more about the ELISA market and latest technological developments in the ELISA market.

FREQUENTLY ASKED QUESTIONS FOR ELISA MARKET:

1. What is ELISA?

ELISA is a type of plate-based diagnostic assay that is designed for detecting and quantifying soluble substances such as peptides, proteins, antibodies, and hormones based on specific reaction between antigen-antibody and thus helping in disease diagnosis.

2. What is the market for the global ELISA?

The global ELISA market was valued at USD 5.34 billion in 2023, growing at a CAGR of 6.07% during the forecast period from 2024 to 2030 to reach USD 7.58 billion by 2030.

3. What are the drivers for the global ELISA market?

The ELISA market is slated to witness prosperity owing to factors such as growing prevalence of infectious and other chronic diseases such as cancer, HIV, and others, increasing research and development activities across biotech and pharmaceutical industries, increasing healthcare expenditure, and the growing focus on improving the accuracy, affordability, portability, and usability of ELISA for end users are further expected to result in the appreciable revenue growth in the ELISA market during the forecast period (2024-2030).

4. Who are the key players operating in the global ELISA market?

Some of the key market players operating in the ELISA market includes Abbott, F. Hoffmann-La Roche Ltd, Erba Mannheim, Synbiotik, Maccura Biotechnology Co., Ltd., Thermo Fisher Scientific, DiaSorin, PerkinElmer Inc., Diatron, Werfen, ALPCO, Agilent, InBios International Inc., Awareness Technology Inc., Elabscience Biotechnology Inc., J. Mitra & Co. Pvt. Ltd., Rayto Life and Analytical Sciences Co.,Ltd., BD, Trivitron Healthcare, and others.

5. Which region has the highest share in the ELISA market?

North America is expected to dominate the overall ELISA Market during the forecast period, 2024 to 2030. This can be ascribed to the presence of large patient pool associated with infectious and other diseases, high consumer awareness regarding new market launches, government support, and a highly potent market in terms of product development and launches, and the local presence of key market players among other factors in the region.

Table of Contents

1. ELISA Market Report Introduction

2. ELISA Market Executive Summary

• 2.1 Scope of the Study
• 2.2 Market at Glance
• 2.3 Competitive Assessment
• 2.4 Financial Benchmarking

3. Regulatory Analysis

• 3.1 The United States
• 3.2 Europe
• 3.3 Japan
• 3.4 China

4. ELISA Market Key Factors Analysis

• 4.1 ELISA Market Drivers
  • 4.1.1 Increasing prevalence of infectious diseases
  • 4.1.2 Rising demand of ELISA for drug abuse testing
  • 4.1.3 Expanding the applications of ELISA in oncology
• 4.2 ELISA Market Restraints and Challenges
  • 4.2.1 Availability of alternative products
  • 4.2.2 Limitations associated with ELISA
• 4.3 ELISA Market Opportunities
  • 4.3.1 Increasing healthcare expenditure
  • 4.3.2 Increasing demand for cost effective diagnostic tools

5. ELISA Market Porter's Five Forces Analysis

• 5.1 Bargaining Power of Suppliers
• 5.2 Bargaining Power of Consumers
• 5.3 Threat of New Entrants
• 5.4 Threat of Substitutes
• 5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on ELISA Market

7. ELISA Market Layout

• 7.1 By Product Type
  • 7.1.1 Kits and Reagents
  • 7.1.2 ELISA Systems
  • 7.1.3 Others
• 7.2 By Application
  • 7.2.1 HIV
  • 7.2.2 Pregnancy Testing
  • 7.2.3 COVID-19
  • 7.2.4 Others
• 7.3 By End-users
  • 7.3.1 Hospitals and Diagnostic Labs
  • 7.3.2 Pharmaceutical & Biotech Industries
  • 7.3.3 Others
• 7.4 By Geography
  • 7.4.1 North America
    • 7.4.1.1 United States ELISA Market in USD million (2021-2030)
    • 7.4.1.2 Canada ELISA Market in USD million (2021-2030)
    • 7.4.1.3 Mexico ELISA Market in USD million (2021-2030)
  • 7.4.2 Europe
    • 7.4.2.1 France ELISA Market in USD million (2021-2030)
    • 7.4.2.2 Germany ELISA Market in USD million (2021-2030)
    • 7.4.2.3 United Kingdom ELISA Market in USD million (2021-2030)
    • 7.4.2.4 Italy ELISA Market in USD million (2021-2030)
    • 7.4.2.5 Spain ELISA Market in USD million (2021-2030)
    • 7.4.2.6 Rest of Europe ELISA Market in USD million (2021-2030)
  • 7.4.3 Asia-Pacific
    • 7.4.3.1 China ELISA Market in USD million (2021-2030)
    • 7.4.3.2 Japan ELISA Market in USD million (2021-2030)
    • 7.4.3.3 India ELISA Market in USD million (2021-2030)
    • 7.4.3.4 Australia ELISA Market in USD million (2021-2030)
    • 7.4.3.5 South Korea ELISA Market in USD million (2021-2030)
    • 7.4.3.6 Rest of Asia Pacific ELISA Market in USD million (2021-2030)
  • 7.4.4 Rest of the World (RoW)
    • 7.4.4.1. Middle East ELISA Market in USD million (2021-2030)
    • 7.4.4.2 Africa ELISA Market in USD million (2021-2030)
    • 7.4.4.3 South America ELISA Market in USD million (2021-2030)

8. ELISA Market Global Company Share Analysis - Key 3-5 Companies

9. ELISA Market Company and Product Profiles

• 9.1 Abbott
  • 9.1.1. Company Overview
  • 9.1.2. Company Snapshot
  • 9.1.3. Financial Overview
  • 9.1.4. Product Listing
  • 9.1.5. Entropy
• 9.2 Erba Mannheim
  • 9.2.1. Company Overview
  • 9.2.2. Company Snapshot
  • 9.2.3. Financial Overview
  • 9.2.4. Product Listing
  • 9.2.5. Entropy
• 9.3 Synbiotik
  • 9.3.1. Company Overview
  • 9.3.2. Company Snapshot
  • 9.3.3. Financial Overview
  • 9.3.4. Product Listing
  • 9.3.5. Entropy
• 9.4 F. Hoffmann-La Roche Ltd
  • 9.4.1. Company Overview
  • 9.4.2. Company Snapshot
  • 9.4.3. Financial Overview
  • 9.4.4. Product Listing
  • 9.4.5. Entropy
• 9.5 Maccura Biotechnology Co.
  • 9.5.1. Company Overview
  • 9.5.2. Company Snapshot
  • 9.5.3. Financial Overview
  • 9.5.4. Product Listing
  • 9.5.5. Entropy
• 9.6 DiaSorin
  • 9.6.1. Company Overview
  • 9.6.2. Company Snapshot
  • 9.6.3. Financial Overview
  • 9.6.4. Product Listing
  • 9.6.5. Entropy
• 9.7 Thermo Fisher Scientific
  • 9.7.1. Company Overview
  • 9.7.2. Company Snapshot
  • 9.7.3. Financial Overview
  • 9.7.4. Product Listing
  • 9.7.5. Entropy
• 9.8 PerkinElmer Inc.
  • 9.8.1. Company Overview
  • 9.8.2. Company Snapshot
  • 9.8.3. Financial Overview
  • 9.8.4. Product Listing
  • 9.8.5. Entropy
• 9.9 Diatron
  • 9.9.1. Company Overview
  • 9.9.2. Company Snapshot
  • 9.9.3. Financial Overview
  • 9.9.4. Product Listing
  • 9.9.5. Entropy
• 9.10 Trivitron Healthcare
  • 9.10.1. Company Overview
  • 9.10.2. Company Snapshot
  • 9.10.3. Financial Overview
  • 9.10.4. Product Listing
  • 9.10.5. Entropy
• 9.11 Werfen
  • 9.11.1. Company Overview
  • 9.11.2. Company Snapshot
  • 9.11.3. Financial Overview
  • 9.11.4. Product Listing
  • 9.11.5. Entropy
• 9.12 BD
  • 9.12.1. Company Overview
  • 9.12.2. Company Snapshot
  • 9.12.3. Financial Overview
  • 9.12.4. Product Listing
  • 9.12.5. Entropy
• 9.13 ALPCO
  • 9.13.1. Company Overview
  • 9.13.2. Company Snapshot
  • 9.13.3. Financial Overview
  • 9.13.4. Product Listing
  • 9.13.5. Entropy
• 9.14 Quidel Corporation
  • 9.14.1. Company Overview
  • 9.14.2. Company Snapshot
  • 9.14.3. Financial Overview
  • 9.14.4. Product Listing
  • 9.14.5. Entropy
• 9.15 Agilent
  • 9.15.1. Company Overview
  • 9.15.2. Company Snapshot
  • 9.15.3. Financial Overview
  • 9.15.4. Product Listing
  • 9.15.5. Entropy
• 9.16 InBios International, Inc
  • 9.16.1. Company Overview
  • 9.16.2. Company Snapshot
  • 9.16.3. Financial Overview
  • 9.16.4. Product Listing
  • 9.16.5. Entropy
• 9.17 Awareness Technology, Inc.
  • 9.17.1. Company Overview
  • 9.17.2. Company Snapshot
  • 9.17.3. Financial Overview
  • 9.17.4. Product Listing
  • 9.17.5. Entropy
• 9.18 Elabscience Biotechnology Inc
  • 9.18.1. Company Overview
  • 9.18.2. Company Snapshot
  • 9.18.3. Financial Overview
  • 9.18.4. Product Listing
  • 9.18.5. Entropy
• 9.19 J. Mitra & Co. Pvt. Ltd.
  • 9.19.1. Company Overview
  • 9.19.2. Company Snapshot
  • 9.19.3. Financial Overview
  • 9.19.4. Product Listing
  • 9.19.5. Entropy
• 9.20 Rayto Life and Analytical Sciences Co.,Ltd.
  • 9.20.1. Company Overview
  • 9.20.2. Company Snapshot
  • 9.20.3. Financial Overview
  • 9.20.4. Product Listing
  • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us